Monitor the vote outcomes on the share increase and executive compensation, as these could signal management's capital allocation strategy and governance priorities. The recent board reshuffle suggests ongoing governance adjustments worth watching.
SLDB drugs
SLDB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 24 $7.92entry
- T+1 · 7mo ago −5.30%α −5.47% · $7.50
- T+5 · 7mo ago −8.33%α −9.24% · $7.26
- T+20 · 6mo ago −17.93%α −21.96% · $6.50
- T+60 · 4mo ago +6.82%α +1.74% · $8.46
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratification of Ilan Ganot's board appointment, a share increase to 480 million, and advisory votes on executive compensation. This follows a recent board reshuffle where Ganot was reappointed to a different class, indicating ongoing governance adjustments.
Key Financial Metrics
Key Facts
- Election of Class II directors Clare Kahn, Adam Stone, and Lynne Sullivan
- Ratification of Ilan Ganot's appointment to Class I director
- Ratification of PricewaterhouseCoopers as independent auditor
- Proposal to increase authorized shares from 240M to 480M
- Advisory vote on executive compensation
Financial Impact
Potential dilution from share increase from 240M to 480M authorized shares
Risk Factors
- Potential shareholder dilution if the share increase is approved and utilized
- Governance concerns if executive compensation receives significant opposition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-173684 |
| Document: 0001193125-26-173684-index-headers.html | 0001193125-26-173684 |
| Document: 0001193125-26-173684-index.html | 0001193125-26-173684 |
| Document: 0001193125-26-173684.txt | 0001193125-26-173684 |
Track record
14 reports on SLDB
5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
- Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
- May 12, 202626w ago Press Release Bearish 6/10 Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
- May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
- Apr 23, 202629w ago DEFA14A Neutral 3/10 Viewing Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
- Apr 10, 202631w ago 8-K Neutral 2/10 Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
- Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers